MX2022012359A - Formulacion. - Google Patents

Formulacion.

Info

Publication number
MX2022012359A
MX2022012359A MX2022012359A MX2022012359A MX2022012359A MX 2022012359 A MX2022012359 A MX 2022012359A MX 2022012359 A MX2022012359 A MX 2022012359A MX 2022012359 A MX2022012359 A MX 2022012359A MX 2022012359 A MX2022012359 A MX 2022012359A
Authority
MX
Mexico
Prior art keywords
formulations
treatment
bacterial
disclosed
inflammatory diseases
Prior art date
Application number
MX2022012359A
Other languages
English (en)
Inventor
Philippe Andres
Morten Sommer
Rasmus Toft-Kehler
Anne Katrine Toft-Kehler
Günter Ditzinger
Mads Jellingsoe
Matthias Manne Knopp
Original Assignee
Union Therapeutics As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2004844.3A external-priority patent/GB202004844D0/en
Priority claimed from GBGB2005340.1A external-priority patent/GB202005340D0/en
Priority claimed from GBGB2010573.0A external-priority patent/GB202010573D0/en
Priority claimed from GBGB2016274.9A external-priority patent/GB202016274D0/en
Priority claimed from GBGB2103970.6A external-priority patent/GB202103970D0/en
Application filed by Union Therapeutics As filed Critical Union Therapeutics As
Publication of MX2022012359A publication Critical patent/MX2022012359A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/609—Amides, e.g. salicylamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a formulaciones que comprenden una salicilanilida halogenada, o una sal farmacéuticamente aceptable de la misma, y una ciclodextrina. Las formulaciones pueden estar en forma de una formulación líquida, particularmente una formulación acuosa, y proporcionar concentraciones altas de salicilanilida halogenada solubilizada. También se desvelan formulaciones en forma de polvos y aerosoles. También se desvelan las formulaciones para su uso en el tratamiento de infecciones bacterianas y víricas, y el tratamiento de enfermedades inflamatorias. Las formulaciones son particularmente adecuadas para la administración por inhalación para el tratamiento de infecciones pulmonares bacterianas y víricas, y el tratamiento de enfermedades inflamatorias pulmonares.
MX2022012359A 2020-04-01 2021-03-26 Formulacion. MX2022012359A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB2004844.3A GB202004844D0 (en) 2020-04-01 2020-04-01 Treatment
GBGB2005340.1A GB202005340D0 (en) 2020-04-09 2020-04-09 Formulation
GBGB2010573.0A GB202010573D0 (en) 2020-07-09 2020-07-09 Formulation
GBGB2016274.9A GB202016274D0 (en) 2020-10-14 2020-10-14 Formulation
GBGB2103970.6A GB202103970D0 (en) 2021-03-22 2021-03-22 Formulation
PCT/EP2021/058047 WO2021198116A1 (en) 2020-04-01 2021-03-26 Formulation

Publications (1)

Publication Number Publication Date
MX2022012359A true MX2022012359A (es) 2022-10-21

Family

ID=75302584

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012359A MX2022012359A (es) 2020-04-01 2021-03-26 Formulacion.

Country Status (11)

Country Link
US (1) US20230190685A1 (es)
EP (1) EP4125805A1 (es)
JP (1) JP2023520229A (es)
KR (1) KR20230024883A (es)
CN (1) CN115701983A (es)
AU (1) AU2021247378A1 (es)
BR (1) BR112022019521A2 (es)
CA (1) CA3172166A1 (es)
IL (1) IL296909A (es)
MX (1) MX2022012359A (es)
WO (1) WO2021198116A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2970434T3 (es) 2014-09-12 2024-05-28 Union Therapeutics As Uso antibacteriano de salicilanilidas halogenadas
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
US11419834B2 (en) 2019-02-25 2022-08-23 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide
US11045434B1 (en) 2020-04-01 2021-06-29 UNION therapeutics A/S Niclosamide formulations for treating disease
WO2022076565A1 (en) * 2020-10-07 2022-04-14 Sorrento Therapeutics, Inc. Salicylanilide analogs for use in the treatment of coronavirus
WO2024064209A1 (en) * 2022-09-21 2024-03-28 Data2Discovery, Inc. Compositions and methods for treating mycobacterium infections

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4742083A (en) 1983-08-24 1988-05-03 Lever Brothers Company Method of relieving pain and inflammatory conditions employing substituted salicylamides
DE19953317C1 (de) 1999-11-05 2001-02-01 Pari Gmbh Inhalationsvernebler
DE10004465A1 (de) 2000-02-02 2001-08-16 Pari Gmbh Inhalationsvernebler
DE10022795B4 (de) 2000-05-10 2005-04-14 Pari GmbH Spezialisten für effektive Inhalation Atemgesteuertes Inhalationstherapiegerät
DE10040528A1 (de) 2000-08-18 2002-02-28 Pari Gmbh Inhalationsvorrichtung und Verfahren zur Erzeugung eines Partikelnebels für Inhalationszwecke
DE10102846B4 (de) 2001-01-23 2012-04-12 Pari Pharma Gmbh Aerosolgenerator
DE50102690D1 (de) 2001-10-18 2004-07-29 Pari Gmbh Inhalationstherapievorrichtung
ATE298600T1 (de) 2001-10-18 2005-07-15 Pari Gmbh Inhalationstherapievorrichtung
DE10229889A1 (de) 2002-07-03 2004-01-29 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung
ATE463304T1 (de) 2002-08-02 2010-04-15 Pari Pharma Gmbh Vorrichtung zur erzeugung von flüssigkeitströpfchen
DE10239321B3 (de) 2002-08-27 2004-04-08 Pari GmbH Spezialisten für effektive Inhalation Aerosoltherapievorrichtung
DE10243371B4 (de) 2002-09-18 2006-06-14 Pari GmbH Spezialisten für effektive Inhalation Aeorosoltherapiegerät
DE10250625A1 (de) 2002-10-30 2004-05-19 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung
DE10251864B3 (de) 2002-11-07 2004-06-24 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung
DE10251865B3 (de) 2002-11-07 2004-05-13 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung
DE10257381B4 (de) 2002-12-09 2006-09-14 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung
DE10320143A1 (de) 2003-05-06 2004-12-16 Pari GmbH Spezialisten für effektive Inhalation Vernebleranschlussvorrichtung für Beatmungsgeräte oder dergleichen
TWI343810B (en) * 2003-05-28 2011-06-21 Nat Health Research Institutes A pharmaceutical composition for inhibiting coronavirus
CN1232253C (zh) * 2003-09-30 2005-12-21 浙江省农业科学院 防治家畜血吸虫、肝片吸虫、绦虫和线虫病联合缓释剂及其制备方法
DE10345950A1 (de) 2003-10-02 2005-05-19 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung mit Ventil
DE10347994A1 (de) 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
DE10348237A1 (de) 2003-10-16 2005-05-19 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung mit einem Düsenvernebler
CN1232248C (zh) * 2003-11-25 2005-12-21 浙江省农业科学院 防治家畜蠕虫、螨虫和原虫病联合缓释剂及其制备方法
DE102005006372B4 (de) 2005-02-11 2007-11-29 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung und Verfahren zu deren Betrieb
DE102005006374B3 (de) 2005-02-11 2006-07-20 Pari GmbH Spezialisten für effektive Inhalation Aerosolerzeugungsvorrichtung und Inhalationstherapiegerät mit einer derartigen Vorrichtung
EP1712220A1 (en) 2005-04-15 2006-10-18 PARI GmbH Spezialisten für effektive Inhalation Pharmaceutical aerosol composition
DE102005024779B4 (de) 2005-05-31 2008-02-21 Pari GmbH Spezialisten für effektive Inhalation Atemzuggesteuerte Inhalationstherapievorrichtung
DE102005038619A1 (de) 2005-08-16 2007-02-22 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung mit einer Ampulle für die Bevorratung eines zu vernebelnden Medikaments
PT1981572E (pt) 2006-02-09 2013-02-26 Pari Pharma Gmbh Distribuição pulmonar de inibidor de alfa-i proteinase
DE102006017002B3 (de) 2006-04-11 2007-01-11 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung mit mehrfachen Düsen
EP2049137A4 (en) 2006-08-08 2013-05-01 Univ California SALICYLANILIDES AS AMPLIFIERS OF THE ORAL RELEASE OF THERAPEUTIC PEPTIDES
DE102007012804A1 (de) 2007-03-16 2008-09-25 Pari Pharma Gmbh Aerosolgenerator
DE102008022987A1 (de) 2008-05-09 2009-11-12 Pari Pharma Gmbh Vernebler für Beatmungsmaschinen und Beatmungsmaschine mit einem solchen Vernebler
DE102008054431B3 (de) 2008-12-09 2010-06-17 Pari Pharma Gmbh Aerosoltherapievorrichtung
DE102009001037B4 (de) 2009-02-20 2013-02-21 Pari Pharma Gmbh Inhalationstherapievorrichtung
EP2401013B1 (en) 2009-02-27 2017-04-12 PARI GmbH Spezialisten für effektive Inhalation An aerosol inhalation device
DE102009026636B4 (de) 2009-06-02 2011-04-14 Pari Pharma Gmbh Verfahren zum Verschweißen einer Membran mit einem Träger bei der Herstellung eines Membranverneblers
EP2380618A1 (en) 2010-04-26 2011-10-26 PARI Pharma GmbH Operating method for an aerosol delivery device and aerosol delivery device
EP2457609A1 (en) 2010-11-24 2012-05-30 PARI Pharma GmbH Aerosol generator
ES2832329T3 (es) 2011-06-08 2021-06-10 Pari Pharma Gmbh Generador de aerosol
DE102011079810B4 (de) 2011-07-26 2013-04-04 Pari Pharma Gmbh Einwegampulle zum Einsetzen in einen Aerosolerzeuger
EP2708219A1 (en) 2012-09-12 2014-03-19 PARI Pharma GmbH Opening element for opening an ampoule in an aerosol generation device and aerosol generation device comprising the opening element
EP2735328A1 (en) 2012-11-27 2014-05-28 PARI Pharma GmbH Fluid reservoir for an aerosol generation device, combination of fluid reservoir and primary fluid package, and aerosol generation device for use with the fluid reservoir
EP2883564A1 (en) 2013-12-16 2015-06-17 PARI Pharma GmbH Aerosol delivery device and method of operating the aerosol delivery device
EP2910268A1 (en) 2014-02-25 2015-08-26 PARI Pharma GmbH Inhalator and inhalator set
US10583221B2 (en) * 2014-05-12 2020-03-10 Gholam A. Peyman Method of corneal transplantation or corneal inlay implantation with cross-linking
EP2957349A1 (en) 2014-06-20 2015-12-23 PARI Pharma GmbH Aerosol generator and aerosol delivery device comprising the aerosol generator
DE102014215064A1 (de) 2014-07-31 2016-02-04 Pari GmbH Spezialisten für effektive Inhalation Vernebler
EP2987520A1 (en) 2014-08-18 2016-02-24 PARI Pharma GmbH Fluid reservoir for an aerosol generator and aerosol generator comprising the fluid reservoir
ES2970434T3 (es) 2014-09-12 2024-05-28 Union Therapeutics As Uso antibacteriano de salicilanilidas halogenadas
EP3037120A1 (en) 2014-12-23 2016-06-29 PARI Pharma GmbH Aerosol delivery device and operating method for the aerosol delivery device
EP3127616B1 (en) 2015-08-03 2017-10-18 PARI Pharma GmbH Method of manufacturing a vibratable head for an aerosol generator and vibratable head for an aerosol generator
GB201604484D0 (en) 2016-03-16 2016-04-27 Antibiotx Aps And Københavns Uni University Of Copenhagen Topical antibacterial compositions
US11491123B2 (en) * 2016-06-23 2022-11-08 Health Research, Inc. Pharmaceutical compositions with antiflaviviral activity
CN106360011A (zh) * 2016-10-18 2017-02-01 安徽省义华农牧科技有限公司 一种预防猪患流感的饲料
EP3375473A1 (en) 2017-03-17 2018-09-19 PARI Pharma GmbH Control device for aerosol nebulizer system
CN110650958A (zh) * 2017-03-21 2020-01-03 诺瓦莱德制药公司 用于磷酸二酯酶抑制及其相关病症的治疗剂
WO2019115771A1 (en) 2017-12-15 2019-06-20 Pari Pharma Gmbh Nebuliser system, holding system, combination comprising nebuliser system and holding system, and aerosol administration method
EP3556475A1 (en) 2018-04-20 2019-10-23 PARI GmbH Spezialisten für effektive Inhalation Controller for an aerosol generator
GB201813876D0 (en) 2018-08-24 2018-10-10 Antibiotx As Treatment
CN110279657B (zh) * 2019-07-29 2021-07-27 河南官渡生物工程有限公司 一种氯氰碘柳胺钠注射液及其制备方法
CN110833623A (zh) * 2019-12-20 2020-02-25 沈阳药科大学 氯硝柳胺乙醇胺盐-羟丙基-β-环糊精包合物及其制备

Also Published As

Publication number Publication date
BR112022019521A2 (pt) 2022-11-16
US20230190685A1 (en) 2023-06-22
JP2023520229A (ja) 2023-05-16
AU2021247378A1 (en) 2022-11-10
WO2021198116A1 (en) 2021-10-07
IL296909A (en) 2022-12-01
EP4125805A1 (en) 2023-02-08
KR20230024883A (ko) 2023-02-21
CA3172166A1 (en) 2021-10-07
CN115701983A (zh) 2023-02-14

Similar Documents

Publication Publication Date Title
MX2022012359A (es) Formulacion.
NZ767296A (en) Liquid inhalation formulation comprising rpl554
CA3030422C (en) Stabilizing excipients for therapeutic protein formulations
MY196599A (en) Pharmaceutical compositons comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
TN2012000566A1 (en) Dry powder formulation comprising an antimuscarinic drug
JP2010132695A5 (es)
WO2007067520A3 (en) Lipid-based compositions of antiinfectives for treating pulmonary infections
PH12017502087B1 (en) Tiotropium inhalation solution for nebulization
WO2009043504A3 (en) Use of apelin-36 and optionally beta-melanotropin as therapeutic agents, eg for treating aids or alzheimer
MY180145A (en) Cenicriviroc compositions and methods of making and using the same
WO2014016548A3 (en) Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient
WO2011107436A3 (en) Aqueous clear solutions of fluocinolone acetonide for treatment of otic inflammation
MY159377A (en) Aqueous suspensions of ciclesonide for nebulisation
JOP20200314A1 (ar) تركيبات صيدلانية مستقرة لأجهزة إستنشاق جرعات مضغوطة معايرة الجرعة
UA118192C2 (uk) Противірусна фармацевтична композиція
WO2011093818A3 (en) Pharmaceutical compositions comprising salmeterol and fluticasone
MY191712A (en) Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation
PH12018502521A1 (en) Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof
WO2021243183A8 (en) Formulations and methods for treating acute respiratory distress syndrome, asthma, or allergic rhinitis
MX2020010977A (es) Procedimientos de tratamiento de infecciones fúngicas.
MX2018013475A (es) Acido carboxilico para tratar/prevenir congestion nasal.
EA201890789A1 (ru) Содержащая цинеол композиция для лечения заболеваний носа
WO2011093811A3 (en) Pharmaceutical preparations comprising formoterol and fluticasone
MX2019001854A (es) Formulacion farmaceutica estable que comprende una composicion de tensioactivo pulmonar reconstituido.
MX2021014343A (es) Una composicion de polvo inhalable de dosis fijas que comprende glicopirronio, formoterol y propionato de fluticasona.